bpc-157 human clinical trials safety dosing dosage BPC-157 (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or Regeneration or Risk? A Narrative
Description
For gut-specific conditions, oral delivery may outperform injection

Hello Tracy, i have a client who achieved 936 blood level of B12

against Herpes simplex virus type-2

Swelling (Edema): Swelling in the legs, ankles, or feet due to fluid retention

There are several important reasons to be skeptical that a successful result in a mouse will be replicated in humans